Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release
Authors:
- Kimberley Joanne HatfieldKHKimberley Joanne Hatfield
- Philippe LassallePLPhilippe Lassalle
- Astrid Olsnes KittangAKAstrid Olsnes Kittang
- Elisabeth ErsværEEElisabeth Ersvær
- Øystein BruserudØBØystein Bruserud
- 5 January 2010
- journal article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 19 (2) , 169-183
Abstract
The Tie-2 receptor can bind its agonistic ligand Angiopoietin-1 (Ang-1) and the potential antagonist Ang-2. Tie-2 can be expressed both by primary human acute myeloid leukaemia (AML) cells and endothelial cells, and Tie-2-blocking antibodies are now being evaluated in clinical trials for cancer treatment. We investigated the effects of Tie-2-blocking antibodies, exogenous Ang-2 and pharmacological agents on AML cell proliferation and the release of angioregulatory mediators. Tie-2-blocking antibodies had a growth inhibitory effect on human AML cells co-cultured with microvascular endothelial cells, but this inhibition was not observed when leukaemic cells were co-cultured with fibroblasts or osteoblasts. AML cell viability in co-cultures was not altered by anti-Tie-2. Furthermore, anti-Tie-2 decreased hepatocyte growth factor (HGF) levels and increased CXCL8 levels in co-cultures, whereas the levels of endocan (a proteoglycan released by endothelial cells) were not altered. The only significant effects of exogenous Ang-2 were decreased levels of HGF and endocan. Constitutive AML cell release of agonistic Ang-1 was decreased by the proteasomal inhibitor bortezomib and the specific IkappaB-kinase/NFkappaB inhibitor BMS-345541. We conclude that various strategies for inhibition of Tie-2-mediated signalling should be considered in AML therapy, possibly in combination with other antiangiogenic strategies.Keywords
This publication has 46 references indexed in Scilit:
- MMP-12 induces IL-8/CXCL8 secretion through EGFR and ERK1/2 activation in epithelial cellsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Angiopoietin: A TIE(d) Balance in Tumor AngiogenesisMolecular Cancer Research, 2007
- The proteasome inhibitors bortezomib and PR‐171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cellsBritish Journal of Haematology, 2007
- Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53Blood, 2006
- Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moonAnnals of Oncology, 2005
- In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serumJournal of Cancer Research and Clinical Oncology, 2005
- THE JUN N-TERMINAL KINASE INHIBITOR SP600125 IS A LIGAND AND ANTAGONIST OF THE ARYL HYDROCARBON RECEPTORDrug Metabolism and Disposition, 2003
- New Strategies in the Treatment of Acute Myelogenous Leukemia (AML): In Vitro Culture of AML Cells—The Present Use in Experimental Studies and the Possible Importance for Future Therapeutic ApproachesStem Cells, 2001
- Induction of Apoptosis by SB202190 through Inhibition of p38β Mitogen-activated Protein KinaseJournal of Biological Chemistry, 1998
- PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in VivoJournal of Biological Chemistry, 1995